Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-04-02 17:55:15 ET · period of report 2026-04-01 · accession 0001763494-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-02 17:55 | 2026-04-01 | TVTX | Dube Eric M | CEO, Dir | M - OptEx | $15.46 | +60.0K | 492.9K | +14% | +$927.6K |
| DMT | 2026-04-02 17:55 | 2026-04-01 | TVTX | Dube Eric M | CEO, Dir | S - Sale+OE | $30.93 | -60.0K | 432.9K | -12% | -$1.86M |
| DT | 2026-04-02 17:55 | 2026-04-01 | TVTX | Dube Eric M | CEO, Dir | M - OptEx | $0.00 | -60.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-01 | M | A | 60,000 | $15.46 | 492,886 | D | — | — | |
| 2 | Common | Common Stock | 2026-04-01 | S | D | 34,902 | $30.55 | 457,984 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020. (F2) The weighted average sale price for the transaction reported was $30.55, and the range of prices were between $30.13 and $31.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 3 | Common | Common Stock | 2026-04-01 | S | D | 25,098 | $31.46 | 432,886 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020. (F3) The weighted average sale price for the transaction reported was $31.46, and the range of prices were between $31.15 and $31.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 4 | Derivative | Employee stock option (right to buy) | 2026-04-01 | M | D | 60,000 | $0.00 | 0 | D | $15.46 · — to 2030-01-31 | 60,000 Common Stock | (F4) The stock option is fully vested and exercisable. |